Nazanin Hosseinkhah, PhD

Director of Special Projects Vielight

  • Toronto ON

Dr. Hosseinkhah joined Vielight to discover how light energy could be used to positively impact the brain and the body.

Contact

Vielight

View more experts managed by Vielight

Media

Social

Biography

Nazanin has a MSc in Physics and a PhD in Medical Biophysics from University of Toronto, located at Sunnybrook Hospital.

Naz leads our Covid-19 pivotal clinical trial and manages research projects in collaboration with the University of Alberta and Baycrest Hospital.

Given her background in biophysics, Naz’s passion aligns with Vielight’s goal of discovering how light energy could be used optimally to positively impact human physiology.

Industry Expertise

Health and Wellness
Alternative Medicine
Advanced Medical Equipment
Medical Equipment / Supplies / Distribution

Areas of Expertise

Medical Device Development
Healthcare System
Start-Up
Market Research
Ultrasound Imaging
Ultrasound Contrast Agents
Light Therapy
Project Management
Scietific Research
Teaching

Education

Sharif University of Technology

B.Sc.

Physics

2003

Brock University

M.Sc.

Physics

2006

University of Toronto

Ph.D.

Medical Biophysics

2014

Affiliations

  • IEEE Ultrasonics, Ferroelectrics, and Frequency Control Society : Member

Languages

  • English
  • Persian

Media Appearances

Ontario light therapy clinical trial aims to accelerate recovery from COVID-19

Clinical Trials Ontario  

2021-01-03

The Vielight RX Plus device delivers light therapy to the sternum and the nasal canal. “This device brings a holistic approach to the treatment of COVID-19 patients,” said Nazanin Hosseinkhah, Research Scientist and Physicist at Vielight Inc. “The device stimulates the thymus gland, creates nitric oxide, increases natural killer cells, acts as an anti-inflammatory therapy, and increases cellular energy.”

View More

Articles

Artificial intelligence in outcomes research: a systematic scoping review

Expert Review of Pharmacoeconomics & Outcomes Research

2021

Introduction: Despite the number of systematic reviews on how artificial intelligence is being used in different areas of medicine, there is no study on the scope of artificial intelligence methods used in outcomes research, the cornerstone of health technology assessment (HTA). This systematic scoping review aims to systematically capture the scope of artificial intelligence methods used in outcomes research to enhance decision-makers’ knowledge and broaden perspectives for health technology assessment and adoption. Areas covered: The review identified 370 studies, consisted of artificial intelligence methods applied to adult patients who underwent any health/medical intervention and reported therapeutic, preventive, or prognostic outcomes.

View more

Modulation of cortical oscillations using 10hz near-infrared transcranial and intranasal photobiomodulation: a randomized sham-controlled crossover study

Brain Stimulation

2021

Objectives: To determine if baseline or changes in CNS metabolites in thebasal ganglia (BG) predict response to taVNS-paired feeding, particularly inIDM exposed to uncontrolled hyperglycemia in utero.Methods: Thirty infants, who had brain injury and were G-tube candi-dates, had daily taVNS-paired feeding treatments for 2 weeks, with pre-and post-treatment MRS scans. LCModel quantified metabolite concen-trations were compared pre- and post-taVNS (Mean+/-St.Dev, 15 +/- 8days). Oxidative stress was measured by glutathione (GSH). We performedlogistic regression to predict treatment response with gestational age (GA),metabolite concentrations, treatment days, and IDM status as covariates.

View more

Home-use Photobiomodulation Device Treatment Outcomes for COVID-19

medRxiv

2022

BACKGROUND There is need for non-pharmaceutical treatments for COVID-19. A home-use photobiomodulation (PBM) device was tested as Treatment in a randomized clinical trial. METHODS 294 patients were randomized with equal allocation to Treatment or Standard of Care (Control). 199 qualified for efficacy analyses. The Treatment group self-treated for 20 minutes twice daily, for the first 5 days, and subsequently once daily for 30 days. A validated respiratory questionnaire was used, and patients were monitored remotely. The primary endpoint was the time-to-recovery (3 consecutive days of no sickness) for general sickness. The Kaplan-Meier method and the Cox Proportional Hazards model were primary methods of analyses.

View more

Show All +